Literature DB >> 9796699

NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity.

R Mangues1, T Corral, S Lu, W F Symmans, L Liu, A Pellicer.   

Abstract

We crossed transgenic mice overexpressing the N-ras proto-oncogene (RasTg) with mice carrying one inactivated copy of the NF1 tumor suppressor gene (NF1+/-) to assess their possible cooperation in tumorigenesis. We have found a significant increase in the incidence of lymphomas in animals with both lesions (RasTg NF1+/-), as compared with animals with single lesions. The mechanism of this cooperation appears to be independent of the NF1 GTPase activating activity since the level of Ras-GTP in primary cultures of tumor tissue do not differ among animals with double and with single lesions. Nevertheless, the finding of significantly higher levels of Erk-1 and Erk-2 activation in lymphomas in the RasTg NF1+/- than in the RasTg group suggests that this cooperative effect may be in part explained by increased signaling through the Erk pathways. Consistent with a role for Erk activation in transformation is the additional observation that Erk-1 and Erk-2 activation is significantly increased in lymphomas as compared with normal spleen. This activation is likely to occur by phosphorylation of previously synthesized and inactive Erk proteins since, despite differences in activation, Erk-1 and Erk-2 expression is similar in normal and lymphoid tissue in all groups. The observed cooperation in in vivo lymphomagenesis between N-ras overexpression and NF1 inactivation emphasizes the importance of searching for additional functions for the NF1 protein and of intensifying the screening for NF1 mutations in human lymphomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796699     DOI: 10.1038/sj.onc.1202097

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

1.  The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice.

Authors:  R P Atit; K Mitchell; L Nguyen; D Warshawsky; N Ratner
Journal:  J Invest Dermatol       Date:  2000-06       Impact factor: 8.551

Review 2.  Tnk1/Kos1: a novel tumor suppressor.

Authors:  William Stratford May; Kishalay Hoare; Sarasija Hoare; Mary K Reinhard; Young J Lee; S Paul Oh
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

3.  The ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation.

Authors:  Koichiro Ono; Matthew R Karolak; Jean de la Croix Ndong; Weixi Wang; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2013-04-09       Impact factor: 6.150

4.  CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Authors:  Aubin Moutal; Xiaofang Yang; Wennan Li; Kerry B Gilbraith; Shizhen Luo; Song Cai; Liberty François-Moutal; Lindsey A Chew; Seul Ki Yeon; Shreya S Bellampalli; Chaoling Qu; Jennifer Y Xie; Mohab M Ibrahim; May Khanna; Ki Duk Park; Frank Porreca; Rajesh Khanna
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.